Abstract PD5-08: PD5-08 Drug target activation mapping of matched triple negative primary and axillary lymph node metastases identifies and links the ER-AR-GR steroid hormone receptor axis with downstream AKT activation
Julia Wulfkuhle(University of California, San Francisco), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Claudius Mueller(Mayo Clinic), Rosa I. Gallagher(George Mason University), Joyce O’Shaughnessy(Baylor University Medical Center), Mariaelena Pierobon(George Mason University), Heather Williams, Page E. Blas
Cited by 0
Related Papers
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|960
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
|The Lancet Oncology|2020|541